The 2025-2030 World Outlook for Stem Cell Technologies and Applications
This study covers the world outlook for stem cell technologies and applications across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.
In this report we define the sales of stem cell technologies and applications as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Aastrom Biosciences, Advanced Cell Technology, AgeX Therapeutics, Alder Biopharmaceuticals, Alkem, AllCells, Allergan, AlloSource, Americord, Amgen, Angiocrine Bioscience, Anterogen, Apceth, Arteriocyte, Associated Press, Astellas Pharma, Asterias Biotherapeutics, Athersys, Auriga Ventures, Axiogenesis, Bank a Tooth, Baxter, BaYi Brain Hospital, BioCardia, BioE, Biogenea-Cellgenea, BIOHEART, Biologic Therapies, BioMet Orthopedics, Biosciences, Biotechnology, BioTime, Blackstone, Bloodworks, Bluebird Bio, Brain Somatic Mosaicism, Caladrius Biosciences, California Institute for Regenerative Medicine (CIRM), Calimmune, Capricor, Cardio3, Caribou, Carolinas Cord Blood Bank (CCBB), Casey Eye Institute, Cedars-Sinai Heart Institute, Celgene, Cell Cure Neurosciences, CellCentric, Cellectis, Cellerant Therapeutics, Cellerix, CELLTREE, Cellular Biomedicine Group, Center for International Blood and Marrow Transplant Research (CIBMTR), Cephalon, Cesca Therapeutics, Ceylad, China Cord Blood, Chugai Pharmaceutical Company, CJ CheilJedang, Clal Biotechnologies Industries, Cleveland BioLabs, ClinImmune Labs, Cochrane, Cognate Bioservices, Cook General, Cord Blood America, Cordvida, CRISPR Therapeutics, Cryo-Cell, CryoCord, CryoHaldco, Cryonix CJSC, Cryo-Save, CryoViva, CXR Biosciences, Cynata Therapeutics, Cytori Therapeutics, Denali Ventures, Dendreon, Dong-A Pharmaceuticals Company, Dynamics, Elbit Imaging, Eli Lilly, EpiStem, ESI BIO, EuroStemCell, Evotec, Fate Therapeutics, FDS Pharma, Fondazione Centro San Raffaele, Forbion Capital Partners, Forticell Bioscience, Forty Seven, Fresenius, FUJIFILM Company, Ltd., Future Health Biobank, Gamida Cell, Gemabank, Gene Cell International, Genetrix Group, Geron, Gilead, GlaxoSmithKline, GlobalStem, Globocan, GSK, Howard Hughes Medical Institute, HSCI, Humacyte, Human Stem Cells Institute, Immunocellular Therapeutics, Immunovative Therapies, Indian Department of Biotechnology, Innovative Cellular Therapeutics, Insception Biosciences, Intellia Therapeutics, IntelliCell Biosciences, International, IPS Academia Japan, Isar Medical Centre, Israel Healthcare venture, Japan Institute of Biomedical Research., JCR Pharmaceuticals, JingYuan Bio., Johnson & Johnson, Kirby Institute, Lifebank Cryogenics, LifeCord, LifeMap Sciences, LifeSouth Community Blood Centers, Inc., Lineage Cell Therapeutics, Lonza Group, MaxCyte, Mayo Clinic, MedCell Bioscience, Medipost, Medistem Panama, Medtronic, PLC, Mesoblast, Miltenyi Biotec, National Dental Pulp Laboratory, NeoStem, Neuralstem, Neurolastem, New England Cord Blood Bank, Nohla Therapeutics, Novartis, NovoCell, NurOwn, NuVasive, Ocata Therapeutics, Omidubicel, Oncocyte, Opexa Therapeutics, Orchard Therapeutics, OrLife Bio, Orthofix, Osiris, Pahrump Valley Times, Pfizer, Pharmicell, Pharmsynthez, Plasticell, Pluristem Therapeutics, Polyphor, Poseida Therapeutics, Precious Cell Group, Prix Galien, PsychENCODE, Pulp Laboratory, Q Therapeutics, QYuns Therapeutics, ReCyte Therapeutics, Ree Labs, Regenerative Sciences, Regenerex, Regeneron, Regeneus, Reliance Group, ReNeuron, RepliCel Life Sciences, Reprobank, Reprocell, Riken, Roche, Roslin Cellab, RTI Biologics, RUSNANO, RVC OJSC, SanBio, Sangamo Biosciences, Sanofi, Seneca Biopharma, S-Evans Biosciences, Sorrento Therapeutics, Spinesmith Partners, SSM Cardinal Glennon, St. Jude’s, Stem Cell Bank, Stemcell Technologies, StemCore, Stemcyte, Stemedica Cell Technologies, StemGen, StemImmune, Inc., Stemina Biomarker Discovery, StemSave, Store-a-tooth, SwissMedic, SynBio, Systems, Takara Bio, Takeda, TAP Biosystems, Teva, The Zon Laboratory, TiGenix, Tong Yuan Stem Cell, Tooth Bank, TrakCel, TransCell, Translational Biosciences, U.S. Stem Cell, UCL Business, UniQure, United Therapeutics, US Stem Cell, Inc., Valeant, VAULT Sc, Inc., Vericel, Vesta Therapeutics, ViaCord, ViaCyte, ViroMed, VistaGen Therapeutics, Vita34, Vitro Biopharma, W.L. Gore & Associates, WA Optimum Health Care, and WHO. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).
In this report we define the sales of stem cell technologies and applications as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Aastrom Biosciences, Advanced Cell Technology, AgeX Therapeutics, Alder Biopharmaceuticals, Alkem, AllCells, Allergan, AlloSource, Americord, Amgen, Angiocrine Bioscience, Anterogen, Apceth, Arteriocyte, Associated Press, Astellas Pharma, Asterias Biotherapeutics, Athersys, Auriga Ventures, Axiogenesis, Bank a Tooth, Baxter, BaYi Brain Hospital, BioCardia, BioE, Biogenea-Cellgenea, BIOHEART, Biologic Therapies, BioMet Orthopedics, Biosciences, Biotechnology, BioTime, Blackstone, Bloodworks, Bluebird Bio, Brain Somatic Mosaicism, Caladrius Biosciences, California Institute for Regenerative Medicine (CIRM), Calimmune, Capricor, Cardio3, Caribou, Carolinas Cord Blood Bank (CCBB), Casey Eye Institute, Cedars-Sinai Heart Institute, Celgene, Cell Cure Neurosciences, CellCentric, Cellectis, Cellerant Therapeutics, Cellerix, CELLTREE, Cellular Biomedicine Group, Center for International Blood and Marrow Transplant Research (CIBMTR), Cephalon, Cesca Therapeutics, Ceylad, China Cord Blood, Chugai Pharmaceutical Company, CJ CheilJedang, Clal Biotechnologies Industries, Cleveland BioLabs, ClinImmune Labs, Cochrane, Cognate Bioservices, Cook General, Cord Blood America, Cordvida, CRISPR Therapeutics, Cryo-Cell, CryoCord, CryoHaldco, Cryonix CJSC, Cryo-Save, CryoViva, CXR Biosciences, Cynata Therapeutics, Cytori Therapeutics, Denali Ventures, Dendreon, Dong-A Pharmaceuticals Company, Dynamics, Elbit Imaging, Eli Lilly, EpiStem, ESI BIO, EuroStemCell, Evotec, Fate Therapeutics, FDS Pharma, Fondazione Centro San Raffaele, Forbion Capital Partners, Forticell Bioscience, Forty Seven, Fresenius, FUJIFILM Company, Ltd., Future Health Biobank, Gamida Cell, Gemabank, Gene Cell International, Genetrix Group, Geron, Gilead, GlaxoSmithKline, GlobalStem, Globocan, GSK, Howard Hughes Medical Institute, HSCI, Humacyte, Human Stem Cells Institute, Immunocellular Therapeutics, Immunovative Therapies, Indian Department of Biotechnology, Innovative Cellular Therapeutics, Insception Biosciences, Intellia Therapeutics, IntelliCell Biosciences, International, IPS Academia Japan, Isar Medical Centre, Israel Healthcare venture, Japan Institute of Biomedical Research., JCR Pharmaceuticals, JingYuan Bio., Johnson & Johnson, Kirby Institute, Lifebank Cryogenics, LifeCord, LifeMap Sciences, LifeSouth Community Blood Centers, Inc., Lineage Cell Therapeutics, Lonza Group, MaxCyte, Mayo Clinic, MedCell Bioscience, Medipost, Medistem Panama, Medtronic, PLC, Mesoblast, Miltenyi Biotec, National Dental Pulp Laboratory, NeoStem, Neuralstem, Neurolastem, New England Cord Blood Bank, Nohla Therapeutics, Novartis, NovoCell, NurOwn, NuVasive, Ocata Therapeutics, Omidubicel, Oncocyte, Opexa Therapeutics, Orchard Therapeutics, OrLife Bio, Orthofix, Osiris, Pahrump Valley Times, Pfizer, Pharmicell, Pharmsynthez, Plasticell, Pluristem Therapeutics, Polyphor, Poseida Therapeutics, Precious Cell Group, Prix Galien, PsychENCODE, Pulp Laboratory, Q Therapeutics, QYuns Therapeutics, ReCyte Therapeutics, Ree Labs, Regenerative Sciences, Regenerex, Regeneron, Regeneus, Reliance Group, ReNeuron, RepliCel Life Sciences, Reprobank, Reprocell, Riken, Roche, Roslin Cellab, RTI Biologics, RUSNANO, RVC OJSC, SanBio, Sangamo Biosciences, Sanofi, Seneca Biopharma, S-Evans Biosciences, Sorrento Therapeutics, Spinesmith Partners, SSM Cardinal Glennon, St. Jude’s, Stem Cell Bank, Stemcell Technologies, StemCore, Stemcyte, Stemedica Cell Technologies, StemGen, StemImmune, Inc., Stemina Biomarker Discovery, StemSave, Store-a-tooth, SwissMedic, SynBio, Systems, Takara Bio, Takeda, TAP Biosystems, Teva, The Zon Laboratory, TiGenix, Tong Yuan Stem Cell, Tooth Bank, TrakCel, TransCell, Translational Biosciences, U.S. Stem Cell, UCL Business, UniQure, United Therapeutics, US Stem Cell, Inc., Valeant, VAULT Sc, Inc., Vericel, Vesta Therapeutics, ViaCord, ViaCyte, ViroMed, VistaGen Therapeutics, Vita34, Vitro Biopharma, W.L. Gore & Associates, WA Optimum Health Care, and WHO. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).
1 INTRODUCTION
1.1 OVERVIEW
1.2 WHAT IS LATENT DEMAND AND THE P.I.E.?
1.3 THE METHODOLOGY
1.4 FREQUENTLY ASKED QUESTIONS (FAQ)
2 SUMMARY OF FINDINGS
2.1 THE WORLDWIDE MARKET POTENTIAL
3 AFRICA
3.1 EXECUTIVE SUMMARY
3.2 ALGERIA
3.3 ANGOLA
3.4 BENIN
3.5 BOTSWANA
3.6 BURKINA FASO
3.7 BURUNDI
3.8 CAMEROON
3.9 CAPE VERDE
3.10 CENTRAL AFRICAN REPUBLIC
3.11 CHAD
3.12 COMOROS
3.13 CONGO (FORMERLY ZAIRE)
3.14 COTE D'IVOIRE
3.15 DJIBOUTI
3.16 EGYPT
3.17 EQUATORIAL GUINEA
3.18 ERITREA
3.19 ETHIOPIA
3.20 GABON
3.21 GHANA
3.22 GUINEA
3.23 GUINEA-BISSAU
3.24 KENYA
3.25 LESOTHO
3.26 LIBERIA
3.27 LIBYA
3.28 MADAGASCAR
3.29 MALAWI
3.30 MALI
3.31 MAURITANIA
3.32 MAURITIUS
3.34 MOROCCO
3.35 MOZAMBIQUE
3.36 NAMIBIA
3.37 NIGER
3.38 NIGERIA
3.39 REPUBLIC OF CONGO
3.40 RWANDA
3.41 SAO TOME E PRINCIPE
3.42 SENEGAL
3.43 SIERRA LEONE
3.44 SOMALIA
3.45 SOUTH AFRICA
3.46 SOUTH SUDAN
3.47 ST. HELENA
3.48 SWAZILAND
3.49 TANZANIA
3.50 THE GAMBIA
3.51 TOGO
3.52 TUNISIA
3.53 UGANDA
3.54 WESTERN SAHARA
3.55 ZAMBIA
3.56 ZIMBABWE
4 ASIA
4.1 EXECUTIVE SUMMARY
4.2 BANGLADESH
4.3 BHUTAN
4.4 BRUNEI
4.5 BURMA
4.6 CAMBODIA
4.7 CHINA
4.8 HONG KONG
4.9 INDIA
4.10 INDONESIA
4.11 JAPAN
4.12 LAOS
4.13 MACAU
4.14 MALAYSIA
4.15 MALDIVES
4.16 MONGOLIA
4.17 NEPAL
4.18 NORTH KOREA
4.19 PAPUA NEW GUINEA
4.20 PHILIPPINES
4.21 SEYCHELLES
4.22 SINGAPORE
4.23 SOUTH KOREA
4.24 SRI LANKA
4.25 TAIWAN
4.26 THAILAND
4.27 TIMOR - LESTE, DEMOCRATIC REPUBLIC OF
4.28 VIETNAM
5 EUROPE
5.1 EXECUTIVE SUMMARY
5.2 ALBANIA
5.3 ANDORRA
5.4 AUSTRIA
5.5 BELARUS
5.6 BELGIUM
5.7 BOSNIA AND HERZEGOVINA
5.8 BULGARIA
5.9 CROATIA
5.10 CYPRUS
5.11 CZECH REPUBLIC
5.12 DENMARK
5.13 ESTONIA
5.14 FINLAND
5.15 FRANCE
5.16 GEORGIA
5.17 GERMANY
5.18 GIBRALTAR
5.19 GREECE
5.20 GUERNSEY
5.21 HUNGARY
5.22 ICELAND
5.23 IRELAND
5.24 ISLE OF MAN
5.25 ITALY
5.26 JERSEY
5.27 KAZAKHSTAN
5.28 KOSOVO
5.29 LATVIA
5.30 LIECHTENSTEIN
5.31 LITHUANIA
5.32 LUXEMBOURG
5.33 MACEDONIA
5.34 MALTA
5.35 MOLDOVA
5.36 MONACO
5.37 MONTENEGRO
5.38 NORWAY
5.39 POLAND
5.40 PORTUGAL
5.41 ROMANIA
5.42 RUSSIA
5.43 SAN MARINO
5.44 SERBIA
5.45 SLOVAKIA
5.46 SLOVENIA
5.47 SPAIN
5.48 SWEDEN
5.49 SWITZERLAND
5.50 THE FAROE ISLANDS
5.51 THE NETHERLANDS
5.52 THE UNITED KINGDOM
5.53 UKRAINE
6 LATIN AMERICA
6.1 EXECUTIVE SUMMARY
6.2 ARGENTINA
6.3 BELIZE
6.4 BOLIVIA
6.5 BRAZIL
6.6 CHILE
6.7 COLOMBIA
6.8 COSTA RICA
6.9 ECUADOR
6.10 EL SALVADOR
6.12 GUATEMALA
6.13 GUYANA
6.14 HONDURAS
6.15 MEXICO
6.16 NICARAGUA
6.17 PANAMA
6.18 PARAGUAY
6.19 PERU
6.20 SURINAME
6.21 THE FALKLAND ISLANDS
6.22 URUGUAY
6.23 VENEZUELA
7 NORTH AMERICA & THE CARIBBEAN
7.1 EXECUTIVE SUMMARY
7.2 ANGUILLA
7.3 ANTIGUA AND BARBUDA
7.4 ARUBA
7.5 BARBADOS
7.6 BERMUDA
7.7 CANADA
7.8 CUBA
7.9 CURACAO
7.10 DOMINICA
7.11 DOMINICAN REPUBLIC
7.12 GREENLAND
7.13 GRENADA
7.15 HAITI
7.16 JAMAICA
7.18 MONTSERRAT
7.19 PUERTO RICO
7.20 SINT MAARTEN
7.21 ST PIERRE AND MIQUELON
7.22 ST. KITTS AND NEVIS
7.23 ST. LUCIA
7.24 ST. VINCENT AND THE GRENADINES
7.25 THE BAHAMAS
7.26 THE BRITISH VIRGIN ISLANDS
7.27 THE CAYMAN ISLANDS
7.28 THE U.S. VIRGIN ISLANDS
7.29 THE UNITED STATES
7.30 TRINIDAD AND TOBAGO
7.31 TURKS AND CAICOS ISLANDS
8 OCEANIA
8.1 EXECUTIVE SUMMARY
8.2 AMERICAN SAMOA
8.3 AUSTRALIA
8.4 CHRISTMAS ISLAND
8.6 COOK ISLANDS
8.7 FIJI
8.8 FRENCH POLYNESIA
8.9 GUAM
8.10 KIRIBATI
8.11 MARSHALL ISLANDS
8.12 MICRONESIA FEDERATION
8.13 NAURU
8.14 NEW CALEDONIA
8.15 NEW ZEALAND
8.16 NIUE
8.17 NORFOLK ISLAND
8.18 PALAU
8.19 SOLOMON ISLANDS
8.20 THE NORTHERN MARIANA ISLAND
8.22 TOKELAU
8.23 TONGA
8.24 TUVALU
8.25 VANUATU
8.26 WALLIS AND FUTUNA
8.27 WESTERN SAMOA
9 THE MIDDLE EAST
9.1 EXECUTIVE SUMMARY
9.2 AFGHANISTAN
9.3 ARMENIA
9.4 AZERBAIJAN
9.5 BAHRAIN
9.6 IRAN
9.7 IRAQ
9.8 ISRAEL
9.9 JORDAN
9.10 KUWAIT
9.11 KYRGYZSTAN
9.12 LEBANON
9.13 OMAN
9.14 PAKISTAN
9.15 PALESTINE
9.16 QATAR
9.17 SAUDI ARABIA
9.18 SYRIAN ARAB REPUBLIC
9.19 TAJIKISTAN
9.20 THE UNITED ARAB EMIRATES
9.21 TURKEY
9.22 TURKMENISTAN
9.23 UZBEKISTAN
9.24 YEMEN
10 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
10.1 DISCLAIMERS & SAFE HARBOR
10.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS
1.1 OVERVIEW
1.2 WHAT IS LATENT DEMAND AND THE P.I.E.?
1.3 THE METHODOLOGY
1.4 FREQUENTLY ASKED QUESTIONS (FAQ)
2 SUMMARY OF FINDINGS
2.1 THE WORLDWIDE MARKET POTENTIAL
3 AFRICA
3.1 EXECUTIVE SUMMARY
3.2 ALGERIA
3.3 ANGOLA
3.4 BENIN
3.5 BOTSWANA
3.6 BURKINA FASO
3.7 BURUNDI
3.8 CAMEROON
3.9 CAPE VERDE
3.10 CENTRAL AFRICAN REPUBLIC
3.11 CHAD
3.12 COMOROS
3.13 CONGO (FORMERLY ZAIRE)
3.14 COTE D'IVOIRE
3.15 DJIBOUTI
3.16 EGYPT
3.17 EQUATORIAL GUINEA
3.18 ERITREA
3.19 ETHIOPIA
3.20 GABON
3.21 GHANA
3.22 GUINEA
3.23 GUINEA-BISSAU
3.24 KENYA
3.25 LESOTHO
3.26 LIBERIA
3.27 LIBYA
3.28 MADAGASCAR
3.29 MALAWI
3.30 MALI
3.31 MAURITANIA
3.32 MAURITIUS
3.34 MOROCCO
3.35 MOZAMBIQUE
3.36 NAMIBIA
3.37 NIGER
3.38 NIGERIA
3.39 REPUBLIC OF CONGO
3.40 RWANDA
3.41 SAO TOME E PRINCIPE
3.42 SENEGAL
3.43 SIERRA LEONE
3.44 SOMALIA
3.45 SOUTH AFRICA
3.46 SOUTH SUDAN
3.47 ST. HELENA
3.48 SWAZILAND
3.49 TANZANIA
3.50 THE GAMBIA
3.51 TOGO
3.52 TUNISIA
3.53 UGANDA
3.54 WESTERN SAHARA
3.55 ZAMBIA
3.56 ZIMBABWE
4 ASIA
4.1 EXECUTIVE SUMMARY
4.2 BANGLADESH
4.3 BHUTAN
4.4 BRUNEI
4.5 BURMA
4.6 CAMBODIA
4.7 CHINA
4.8 HONG KONG
4.9 INDIA
4.10 INDONESIA
4.11 JAPAN
4.12 LAOS
4.13 MACAU
4.14 MALAYSIA
4.15 MALDIVES
4.16 MONGOLIA
4.17 NEPAL
4.18 NORTH KOREA
4.19 PAPUA NEW GUINEA
4.20 PHILIPPINES
4.21 SEYCHELLES
4.22 SINGAPORE
4.23 SOUTH KOREA
4.24 SRI LANKA
4.25 TAIWAN
4.26 THAILAND
4.27 TIMOR - LESTE, DEMOCRATIC REPUBLIC OF
4.28 VIETNAM
5 EUROPE
5.1 EXECUTIVE SUMMARY
5.2 ALBANIA
5.3 ANDORRA
5.4 AUSTRIA
5.5 BELARUS
5.6 BELGIUM
5.7 BOSNIA AND HERZEGOVINA
5.8 BULGARIA
5.9 CROATIA
5.10 CYPRUS
5.11 CZECH REPUBLIC
5.12 DENMARK
5.13 ESTONIA
5.14 FINLAND
5.15 FRANCE
5.16 GEORGIA
5.17 GERMANY
5.18 GIBRALTAR
5.19 GREECE
5.20 GUERNSEY
5.21 HUNGARY
5.22 ICELAND
5.23 IRELAND
5.24 ISLE OF MAN
5.25 ITALY
5.26 JERSEY
5.27 KAZAKHSTAN
5.28 KOSOVO
5.29 LATVIA
5.30 LIECHTENSTEIN
5.31 LITHUANIA
5.32 LUXEMBOURG
5.33 MACEDONIA
5.34 MALTA
5.35 MOLDOVA
5.36 MONACO
5.37 MONTENEGRO
5.38 NORWAY
5.39 POLAND
5.40 PORTUGAL
5.41 ROMANIA
5.42 RUSSIA
5.43 SAN MARINO
5.44 SERBIA
5.45 SLOVAKIA
5.46 SLOVENIA
5.47 SPAIN
5.48 SWEDEN
5.49 SWITZERLAND
5.50 THE FAROE ISLANDS
5.51 THE NETHERLANDS
5.52 THE UNITED KINGDOM
5.53 UKRAINE
6 LATIN AMERICA
6.1 EXECUTIVE SUMMARY
6.2 ARGENTINA
6.3 BELIZE
6.4 BOLIVIA
6.5 BRAZIL
6.6 CHILE
6.7 COLOMBIA
6.8 COSTA RICA
6.9 ECUADOR
6.10 EL SALVADOR
6.12 GUATEMALA
6.13 GUYANA
6.14 HONDURAS
6.15 MEXICO
6.16 NICARAGUA
6.17 PANAMA
6.18 PARAGUAY
6.19 PERU
6.20 SURINAME
6.21 THE FALKLAND ISLANDS
6.22 URUGUAY
6.23 VENEZUELA
7 NORTH AMERICA & THE CARIBBEAN
7.1 EXECUTIVE SUMMARY
7.2 ANGUILLA
7.3 ANTIGUA AND BARBUDA
7.4 ARUBA
7.5 BARBADOS
7.6 BERMUDA
7.7 CANADA
7.8 CUBA
7.9 CURACAO
7.10 DOMINICA
7.11 DOMINICAN REPUBLIC
7.12 GREENLAND
7.13 GRENADA
7.15 HAITI
7.16 JAMAICA
7.18 MONTSERRAT
7.19 PUERTO RICO
7.20 SINT MAARTEN
7.21 ST PIERRE AND MIQUELON
7.22 ST. KITTS AND NEVIS
7.23 ST. LUCIA
7.24 ST. VINCENT AND THE GRENADINES
7.25 THE BAHAMAS
7.26 THE BRITISH VIRGIN ISLANDS
7.27 THE CAYMAN ISLANDS
7.28 THE U.S. VIRGIN ISLANDS
7.29 THE UNITED STATES
7.30 TRINIDAD AND TOBAGO
7.31 TURKS AND CAICOS ISLANDS
8 OCEANIA
8.1 EXECUTIVE SUMMARY
8.2 AMERICAN SAMOA
8.3 AUSTRALIA
8.4 CHRISTMAS ISLAND
8.6 COOK ISLANDS
8.7 FIJI
8.8 FRENCH POLYNESIA
8.9 GUAM
8.10 KIRIBATI
8.11 MARSHALL ISLANDS
8.12 MICRONESIA FEDERATION
8.13 NAURU
8.14 NEW CALEDONIA
8.15 NEW ZEALAND
8.16 NIUE
8.17 NORFOLK ISLAND
8.18 PALAU
8.19 SOLOMON ISLANDS
8.20 THE NORTHERN MARIANA ISLAND
8.22 TOKELAU
8.23 TONGA
8.24 TUVALU
8.25 VANUATU
8.26 WALLIS AND FUTUNA
8.27 WESTERN SAMOA
9 THE MIDDLE EAST
9.1 EXECUTIVE SUMMARY
9.2 AFGHANISTAN
9.3 ARMENIA
9.4 AZERBAIJAN
9.5 BAHRAIN
9.6 IRAN
9.7 IRAQ
9.8 ISRAEL
9.9 JORDAN
9.10 KUWAIT
9.11 KYRGYZSTAN
9.12 LEBANON
9.13 OMAN
9.14 PAKISTAN
9.15 PALESTINE
9.16 QATAR
9.17 SAUDI ARABIA
9.18 SYRIAN ARAB REPUBLIC
9.19 TAJIKISTAN
9.20 THE UNITED ARAB EMIRATES
9.21 TURKEY
9.22 TURKMENISTAN
9.23 UZBEKISTAN
9.24 YEMEN
10 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
10.1 DISCLAIMERS & SAFE HARBOR
10.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS
